Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Flexion Therapeutics Inc. Skyrocketed Today

By Brian Feroldi - Mar 23, 2017 at 3:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares shot up 33% on Thursday, fueled by rumors that the company is about to accept a takeover bid.

What happened

Shares of Flexion Therapeutics (FLXN) rose by more than 33% at $26.28 in Thursday trading, in response to rumors that a takeover bid from Sanofi (SNY 1.02%) is looming.

Businessman whispering in the ear of another businessman

Image source: Getty Images.

So what

According to a report by Fierce Pharma, Flexion has accepted a takeover offer from the French pharma giant Sanofi. This information comes from "a source close to the deal," and the bid is said to value the company's shares in the mid-$30s. If true, the deal could easily be worth more than $1 billion.

Flexion's stock ended Wednesday's trading session at $19.68, so if the terms of this deal are to be believed, shareholders would stand to earn a sizable premium. Traders bid up shares today on the hopes that an official announcement will be made soon.

Now what

While it is hard to know what to make of this report, there are reasons this deal would make sense for both companies. Flexion's lead compound, Zilretta, is an extended-release formulation of triamcinolone acetonide that is designed to provide long-lasting relief to knee pain due to osteoarthritis. Currently, Zilretta is pending FDA approval and a decision is expected by Oct. 6, 2017.

This is a market that Sanofi knows well: The company has an injectable osteoarthritis treatment of its own, Synvisc. If Zilretta wins approval, Sanofi's relationships and resources could go a long way toward making the drug's launch a success. 

Of course, without official confirmation from Flexion or Sanofi that this is a done deal, it is hard to know what to make of Fierce Pharma's report. Flexion's shareholders might want to simply enjoy today's gains and hang on to their shares until more information becomes available.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$52.67 (1.02%) $0.53
Flexion Therapeutics, Inc. Stock Quote
Flexion Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.